Mesenchymal Stem Cell Therapy for Parkinson's Disease

Migration, Crosslink

📗 Cite This Artifact

←

Home / Artifacts / Mesenchymal Stem Cell Therapy for Parkinson's Disease

📖

Mesenchymal Stem Cell Therapy for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-mesenchymal-stem-cell-

📖 Wiki Page

therapeutic1605 wordssynced 2026-04-02

Mesenchymal Stem Cell Therapy for Parkinson's Disease

Overview

flowchart TD Mesenchymal_Stem_Cell_Therapy_["Mesenchymal Stem Cell Therapy for Parkinsons Dis"] Mesenchymal_Stem_Cell_Therapy_["Parkinson"] Mesenchymal_Stem_Cell_Therapy_ -->|"related to"| Mesenchymal_Stem_Cell_Therapy_ style Mesenchymal_Stem_Cell_Therapy_ fill:#81c784,stroke:#333,color:#000 Mesenchymal_Stem_Cell_Therapy_["table"] Mesenchymal_Stem_Cell_Therapy_ -->|"related to"| Mesenchymal_Stem_Cell_Therapy_ style Mesenchymal_Stem_Cell_Therapy_ fill:#81c784,stroke:#333,color:#000 Mesenchymal_Stem_Cell_Therapy_["class"] Mesenchymal_Stem_Cell_Therapy_ -->|"related to"| Mesenchymal_Stem_Cell_Therapy_ style Mesenchymal_Stem_Cell_Therapy_ fill:#81c784,stroke:#333,color:#000 style Mesenchymal_Stem_Cell_Therapy_ fill:#4fc3f7,stroke:#333,color:#000

...

Mesenchymal Stem Cell Therapy for Parkinson's Disease

Overview

Mermaid diagram (expand to render)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Mesenchymal Stem Cell Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Treatment Name</td>
<td>Mesenchymal Stem Cell (MSC) Therapy for PD</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Mesenchymal Stromal Cells</td>
</tr>
<tr>
<td class="label">Target Indication</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Neurotrophic secretion, immunomodulation, mitochondrial transfer</td>
</tr>
<tr>
<td class="label">Delivery Routes</td>
<td>Intravenous, intrathecal, stereotactic</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 1/2 trials</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Function in PD</td>
</tr>
<tr>
<td class="label">GDNF</td>
<td>Potent neurotrophin for dopaminergic neurons; promotes survival and process outgrowth</td>
</tr>
<tr>
<td class="label">BDNF</td>
<td>Supports neuronal plasticity, synaptic function, and dopamine signaling</td>
</tr>
<tr>
<td class="label">VEGF</td>
<td>Promotes neurovascular unit health, improves blood-brain barrier function</td>
</tr>
<tr>
<td class="label">IGF-1</td>
<td>Supports neuronal metabolism and survival</td>
</tr>
<tr>
<td class="label">HGF</td>
<td>Anti-inflammatory and neuroprotective properties</td>
</tr>
<tr>
<td class="label">Source</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Bone Marrow (Autologous)</td>
<td>Well-characterized, no immune issues</td>
</tr>
<tr>
<td class="label">Bone Marrow (Allogeneic)</td>
<td>Younger cells, standardized</td>
</tr>
<tr>
<td class="label">Umbilical Cord (Wharton's Jelly)</td>
<td>Higher proliferative capacity, immunomodulatory</td>
</tr>
<tr>
<td class="label">Adipose Tissue</td>
<td>Abundant source, easy collection</td>
</tr>
<tr>
<td class="label">Dental Pulp</td>
<td>Neural crest origin, easy access</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Sponsor</td>
</tr>
<tr>
<td class="label">NCT00911326</td>
<td>Multiple</td>
</tr>
<tr>
<td class="label">NCT01827180</td>
<td>University of Poona</td>
</tr>
<tr>
<td class="label">NCT02611167</td>
<td>Saudi German Hospital</td>
</tr>
<tr>
<td class="label">NCT04521368</td>
<td>Shanghai Sixth People's Hospital</td>
</tr>
<tr>
<td class="label">NCT04881461</td>
<td>HEALIOS K.K. (Japan)</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Advantages</td>
</tr>
<tr>
<td class="label">Intravenous</td>
<td>Minimally invasive, systemic effect</td>
</tr>
<tr>
<td class="label">Intrathecal</td>
<td>Direct CSF delivery, reaches brain surfaces</td>
</tr>
<tr>
<td class="label">Stereotactic</td>
<td>Precise brain targeting, high local concentration</td>
</tr>
<tr>
<td class="label">Intra-arterial</td>
<td>High CNS exposure</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>MSC Therapy</td>
</tr>
<tr>
<td class="label">Primary Mechanism</td>
<td>Neuroprotection, trophic support</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Phase 1/2</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>IV/Intrathecal</td>
</tr>
<tr>
<td class="label">Invasiveness</td>
<td>Lower</td>
</tr>
<tr>
<td class="label">Repeat Dosing</td>
<td>Yes</td>
</tr>
<tr>
<td class="label">Dopamine Restoration</td>
<td>Indirect via trophic support</td>
</tr>
<tr>
<td class="label">Risk of Tumor</td>
<td>Very low</td>
</tr>
<tr>
<td class="label">Manufacturing</td>
<td>Relatively simple</td>
</tr>
<tr>
<td class="label">Timeline to Access</td>
<td>Earlier</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Product</td>
</tr>
<tr>
<td class="label">BrainStorm Cell Therapeutics</td>
<td>MSC-NTF (NurOwn platform)</td>
</tr>
<tr>
<td class="label">HEALIOS K.K.</td>
<td>Allogeneic MSCs</td>
</tr>
<tr>
<td class="label">Cynata Therapeutics</td>
<td>CYP-001</td>
</tr>
</table>

Mesenchymal Stem Cell (MSC) Therapy for Parkinson's Disease represents a distinct therapeutic approach from the dopaminergic neuron replacement strategies (iPSC/ESC-derived neurons). While cell replacement aims to substitute lost [dopaminergic neurons](/cell-types/vulnerable-dopaminergic-pd), MSC therapy focuses on neuroprotection, immunomodulation, and trophic support to preserve remaining neurons and slow disease progression.

Rationale for MSC Therapy in PD

Why Neuroprotection Over Replacement?

Several factors make MSC-based neuroprotection an attractive complementary approach:

Preserve Existing Circuitry: Rather than rebuilding neural circuits (which requires precise integration), MSC therapy protects the [substantia nigra pars compacta](/brain-regions/substantia-nigra) neurons that remain

Multi-Target Mechanism: Addresses multiple pathogenic pathways simultaneously (inflammation, oxidative stress, mitochondrial dysfunction)

Accessibility: MSCs can be delivered via less invasive routes than stereotactic neuron transplantation

Repeat Dosing: Multiple administrations possible as disease progresses

Combination Potential: Can be combined with other disease-modifying approaches

Disease Context

[Parkinson's disease](/diseases/parkinsons-disease) involves:

Progressive loss of [dopaminergic neurons](/cell-types/substantia-nigra-dopamine-parkinsons) in the [substantia nigra](/brain-regions/substantia-nigra)
[Alpha-synuclein](/proteins/alpha-synuclein) aggregation into [Lewy bodies](/entities/lewy-bodies)
Chronic [neuroinflammation](/mechanisms/neuroinflammation) with activated [microglia](/cell-types/microglia)
Mitochondrial dysfunction and oxidative stress
Neurotrophic factor deficiency

MSC therapy directly addresses several of these mechanisms.

Mechanism of Action

Immunomodulation

MSCs exert powerful immunomodulatory effects critical for PD:

Microglial Modulation

Shift [microglia](/cell-types/microglia) from pro-inflammatory M1 to protective M2 phenotype
Reduce production of pro-inflammatory cytokines (IL-1β, TNF-α, IFN-γ)
Increase anti-inflammatory cytokines (IL-10, TGF-β)

T-Cell Regulation

Suppress pro-inflammatory T-cell responses
Promote regulatory T-cell (Treg) populations
Reduce autoimmunity that may contribute to neurodegeneration

Neurotrophic Factor Secretion

MSCs secrete multiple neurotrophic factors that support [dopaminergic neuron](/cell-types/vulnerable-dopaminergic-pd) survival:

Mitochondrial Transfer

A unique mechanism by which MSCs transfer functional mitochondria to damaged neurons:

Tunneling Nanotubes: Form direct cytoplasmic connections with stressed neurons
Metabolic Rescue: Restore ATP levels in neurons with impaired energy metabolism
Bioenergetic Support: Improve neuronal viability under oxidative stress conditions
Particularly Relevant in PD: Mitochondrial dysfunction is a core feature of [Parkinson's disease pathogenesis](/mechanisms/mitochondrial-dysfunction-parkinson)

Anti-Apoptotic Effects

Secreted factors activate pro-survival signaling cascades (PI3K/Akt, MAPK/ERK)
Reduce caspase activation and programmed cell death
Protect neurons from excitotoxicity
Preserve synaptic connections

Alpha-Synuclein Modulation

Emerging evidence suggests MSCs may influence [alpha-synuclein](/proteins/alpha-synuclein) pathology:

Exosome-mediated clearance mechanisms
Reduction of [alpha-synuclein aggregation](/mechanisms/alpha-synuclein-aggregation-pathway)
Protection against prion-like spread

MSC Sources for PD Therapy

Clinical Trials in Parkinson's Disease

Completed and Active Trials

Key Clinical Findings

Phase 1/2 Trials (2014-2016)

MSC transplantation was safe and well-tolerated
Some patients showed improved motor scores (UPDRS Part III)
No significant adverse events related to cell administration
Reference: PMID:24721108, PMID:28182767

Mechanism Evidence

Elevated neurotrophic factors in CSF of treated patients
PET imaging showed reduced neurodegeneration in some patients
Immunomodulatory effects confirmed in biomarker studies

Ongoing Programs

HEALIOS K.K. (Japan)

Allogeneic MSC product
Phase 1/2 trial for PD
Focus on safety and preliminary efficacy

International Consortium Trials

Multi-center trials combining different MSC sources
Focus on optimizing delivery routes and cell dosing

Delivery Routes Comparison

Optimal Route Selection

For PD, intrathecal or intravenous delivery is most commonly used:

Allows repeated administrations
Targets neuroinflammation systemically
Less invasive than neurosurgery

Stereotactic delivery targets [substantia nigra](/brain-regions/substantia-nigra) directly but is more invasive.

Comparison: MSC vs. Dopaminergic Neuron Replacement

Complementary Approaches

These approaches are not mutually exclusive:

Early Disease: MSC therapy to protect neurons and slow progression
Later Disease: Neuron replacement when significant cell loss has occurred
Combination: MSC therapy alongside neuron replacement for synergistic effects

Companies and Programs

Clinical-Stage Programs

Research Programs

Multiple universities in Korea, Japan, China, and Europe have active MSC-PD programs
International Stem Cell Corporation (ISCO) exploring MSC derivatives for PD

Therapeutic Potential and Challenges

Potential Benefits

Disease Modification: Targets multiple pathogenic pathways simultaneously

Neuroprotection: Preserves remaining dopaminergic neurons

Symptomatic Relief: May improve motor function through trophic support

Autologous Option: Patient's own cells reduce rejection risk

Repeat Administrations: Can be re-treated as disease progresses

Accessible: Less invasive than surgical cell transplantation

Challenges

Limited CNS Delivery: Blood-brain barrier limits intravenous delivery

Variable Potency: MSC preparations vary between donors and sources

Survival in CNS: Unclear how long administered MSCs persist

Optimal Dose: Not established for PD

Durability: Unknown duration of benefit

Regulatory Pathway: Cell therapy regulatory challenges

Patient Selection Considerations

MSC therapy may be most appropriate for:

Early-to-mid stage PD (Hoehn & Yahr 1-3)
Patients with significant neuroinflammation markers
Those seeking disease-modifying approaches
Patients with contraindications to surgical interventions

Combination Therapies

Synergistic Approaches

MSC therapy may be enhanced when combined with:

GDNF/BDNF Direct Delivery: Combined trophic support

Small Molecules: MAO-B inhibitors, dopamine agonists

Immunomodulatory Drugs: Anti-inflammatory agents

Physical Therapy: Rehabilitation to enhance functional outcomes

Gene Therapy: AAV-based neurotrophic factor expression

Research Pipeline

MSC plus neurotrophic factor combination trials in planning
Gene-modified MSCs (enhanced GDNF secretion) in preclinical development
MSC-derived exosomes as cell-free alternative

Safety Profile

Observed Safety in PD Trials

Generally well-tolerated across trials
Common adverse events: Headache, injection site pain
No significant immune reactions with autologous cells
No tumor formation observed in long-term follow-up
Low rates of serious adverse events

Long-Term Monitoring

Continued monitoring for potential delayed effects
Assessment of durability of benefit
Impact on disease progression over years

Future Directions

Next-Generation Approaches

Gene-Enhanced MSCs: Engineering MSCs to produce higher GDNF/BDNF levels

Exosome Therapy: Cell-free alternative using MSC-derived exosomes

Biomaterial Scaffolds: Supporting MSC survival and distribution

Combination Approaches: MSC therapy with other disease-modifying agents

Clinical Development Needs

Larger, controlled trials with standardized endpoints
Biomarker development to predict response
Optimal patient selection criteria
Long-term follow-up studies
Comparison of delivery routes

References

[Ventimiglia et al., Mesenchymal Stem Cells for Parkinson's Disease Neurodegeneration. Cells (2022)](https://doi.org/10.3390/cells11071158)

[Daniele et al., Therapeutic potential of MSC in Parkinson's disease. J Transl Med (2021)](https://pubmed.ncbi.nlm.nih.gov/34266456/)

[Park et al., MSC exosomes ameliorate alpha-synuclein aggregation. Mol Brain (2021)](https://pubmed.ncbi.nlm.nih.gov/34238314/)

[Schiess et al., Phase 1/2a trial of autologous MSC therapy for Parkinson's disease. Nat Med (2022)](https://doi.org/10.1038/s41591-022-01789-0)

[Intrastriatal transplantation of autologous mesenchymal stem cells. Eur J Neurol (2007)](https://pubmed.ncbi.nlm.nih.gov/17666013/)

📖 View canonical wiki page →

Related Entities

therapeutics-mesenchymal-stem-cell-therapy-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-mesenchymal-stem-cell-therapy-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-04b172092fd9
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-mesenchymal-stem-cell-therapy-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

Incoming

121

Outgoing

151

0 supporting 0 contradicting 0 neutral

View full evidence profile →

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

This artifact has no version history yet.

Linked Artifacts (266)

derives_from?Biomaterial Scaffolds90%

derives_from?Combination Approaches90%

related🧪Bacterial Enzyme-Mediated Dopamine Precursor Synthesis90%

derives_from?Exosome Therapy90%

derives_from?Gene-Enhanced MSCs90%

mentions🧪Bacterial Enzyme-Mediated Dopamine Precursor Synthesis90%

related🧫Macroautophagy Dysfunction in PD - Experiment Design70%

related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%

related🧫Macroautophagy Dysfunction in PD - Experiment Design70%

mentions🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna69%

mentions🧪Vagal Afferent Microbial Signal Modulation68%

mentions🧪Vocal Cord Neuroplasticity Stimulation63%

related🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna62%

related🧪Vagal Afferent Microbial Signal Modulation61%

related🧫Multiscale Computational Modeling of Protein Aggregation Kin60%

related🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne60%

related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#60%

related🧫CRISPR Gene Correction Approaches for CBS/PSP60%

related🧫MLCS Quantification in Parkinson's Disease60%

related🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D60%

related🧫Stress Granule Dysfunction Validation in Parkinson's Di60%

related🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim60%

related🧫AAV-LRRK2 IND-Enabling Study Design60%

related🧫Alpha-Synuclein Seed Amplification Assay Validation60%

related🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design60%

related🧫Exercise-BDNF-Mitophagy Biomarker Study in PD60%

related🧫Computational Modeling of Alpha-Synuclein Propagation in PD60%

related🧫Antiviral Therapy Trial for Parkinson's Disease60%

related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag60%

related🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper60%

related🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me60%

related🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&60%

related🧫Combination Therapy Sequencing in Parkinson's Disease60%

related🧫Ferroptosis Validation in Parkinson's Disease60%

related🧫Neural Oscillation Dysfunction Validation in Parkinson'60%

related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera60%

related🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr60%

related🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise60%

related🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i60%

related🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back60%

related🧫GLP-1 Agonist Neuroprotection Mechanism in PD60%

related🧫Peroxisomal Dysfunction Validation in Parkinson's Disea60%

related🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#60%

related🧫Parkinson's Disease Subtype Classification — Precision 60%

related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#60%

related🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P60%

related🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson60%

related🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&60%

related🧫Peroxisome Dysfunction Validation in Parkinson's Diseas60%

related🧫Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa60%

related🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation60%

related🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki60%

related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&60%

related🧫Sirtuin Dysfunction Validation in Parkinson's Disease60%

related🧫Regulated Necrosis Validation Study in Parkinson's Dise60%

related🧫Non-Motor Symptom Progression in Parkinson's Disease — 60%

related🧫Epigenetic Dysregulation Validation in Parkinson's Dise60%

related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin60%

related🧫Experiment: Multi-Ethnic PD GWAS60%

related🧫Prodromal Parkinson's Disease Biomarker Development — E60%

related🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation60%

related🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 60%

related🧫Validation: Membrane-Nucleation in iPSC Neurons60%

related🧫Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown60%

related🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio60%

related🧫cGAS-STING Pathway Validation Study in Parkinson's Dise60%

related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD60%

related🧫Purinergic Signaling Dysfunction Validation in Parkinson60%

related🧫Axonal Transport Dysfunction Validation in Parkinson's 60%

related🧫Cytochrome Therapeutics60%

related🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 60%

related🧪Vocal Cord Neuroplasticity Stimulation56%

related🧫Validate Mitochondria-Lysosome Contact Site Dysfunction in P54%

related🧫Axonal Transport Dysfunction Validation in Parkinson's 54%

related🧫LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Ne54%

related🧫Alpha-Synuclein Seed Amplification Assay Validation54%

related🧫Peroxisomal Dysfunction Validation in Parkinson's Disea54%

related🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me54%

related🧫Parkinson's Disease Subtype Classification — Precision 54%

related🧫cGAS-STING Pathway Validation Study in Parkinson's Dise54%

related🧫Ferroptosis Validation in Parkinson's Disease54%

related🧫DNA Damage Repair Deficiency Validation Study in Parkinson&#54%

related🧫Experiment Design: Metal Ion-Synuclein-Mitochondria Axis in 54%

related🧫Metabolic Syndrome-Parkinson's Disease Axis Clinical Tr54%

related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#54%

related🧫Experiment: Multi-Ethnic PD GWAS54%

related🧫Exercise-BDNF-Mitophagy Biomarker Study in PD54%

related🧫NLRP3 Inflammasome Validation Study in Parkinson's Dise54%

related🧫Antiviral Therapy Trial for Parkinson's Disease54%

related🧫Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson54%

related🧫Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa54%

related🧫Combination Therapy Sequencing in Parkinson's Disease54%

related🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio54%

related🧫AAV-LRRK2 Gene Therapy IND-Enabling Study Design54%

related🧫Computational Modeling of Alpha-Synuclein Propagation in PD54%

related🧫Non-Dopaminergic Neurotransmitter Degeneration in PD - Exper54%

related🧫Non-Motor Symptom Progression in Parkinson's Disease — 54%

related🧫Synaptic Vesicle Trafficking Dysfunction Validation in Parki54%

related🧫Neural Oscillation Dysfunction Validation in Parkinson'54%

related🧫Regulated Necrosis Validation Study in Parkinson's Dise54%

related🧫Mechanism: Selective Vulnerability of Dopaminergic Neurons i54%

related🧫Chaperone-Mediated Autophagy Dysfunction in PD - Experiment 54%

related🧫Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson&54%

related🧫Purinergic Signaling Dysfunction Validation in Parkinson54%

related🧫Stress Granule Dysfunction Validation in Parkinson's Di54%

related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag54%

related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&54%

related🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim54%

related🧫Alpha-Synuclein SAA Kinetics Study — Biological Staging Back54%

related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin54%

related🧫Validation: Membrane-Nucleation in iPSC Neurons54%

related🧫AAV-LRRK2 IND-Enabling Study Design54%

related🧫Sirtuin Dysfunction Validation in Parkinson's Disease54%

related🧫Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation54%

related🧫Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation54%

related🧫Sirtuin Pathway Dysfunction Validation in Parkinson's D54%

related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD54%

related🧫MLCS Quantification in Parkinson's Disease54%

related🧫Cytochrome Therapeutics54%

related🧫CRISPR Gene Correction Approaches for CBS/PSP54%

related🧫Synaptic Mitochondrial Resilience Enhancement for Parkinson&54%

related🧫Prodromal Parkinson's Disease Biomarker Development — E54%

related🧫Peroxisome Dysfunction Validation in Parkinson's Diseas54%

related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#54%

related🧫Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown54%

related🧫Multiscale Computational Modeling of Protein Aggregation Kin54%

related🧫AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera54%

related🧫Epigenetic Dysregulation Validation in Parkinson's Dise54%

related🧫GLP-1 Agonist Neuroprotection Mechanism in PD54%

related🔬What are the most promising therapeutic strategies for targe50%

mentions🧪Orexin-Microglia Modulation Therapy50%

related🔬Senescent cell clearance as neurodegeneration therapy50%

mentions🧪Ganglioside Rebalancing Therapy50%

related🔬What are the mechanisms underlying synaptic pruning by micro50%

mentions🧪Glial Glycocalyx Remodeling Therapy50%

related🔬What are the mechanisms underlying 4r-tau strain-specific sp50%

related🔬What are the mechanisms underlying mitochondrial transfer be50%

mentions🧪HCN1-Mediated Resonance Frequency Stabilization Therapy50%

related🔬What are the mechanisms underlying epigenetic clocks and bio50%

related🔬What are the mechanisms underlying digital biomarkers and ai50%

related🔬What are the mechanisms underlying what are the mechanisms b50%

related🔬What are the mechanisms underlying senolytic therapy for age50%

related🔬How to break the GBA-alpha-synuclein bidirectional loop for 50%

related🔬What are the mechanisms underlying senolytic therapy for age50%

related🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph50%

related🔬What are the mechanisms underlying what are the mechanisms b50%

mentions🧪Near-infrared light therapy stimulates COX4-dependent mitoch50%

mentions🧫tACS Connectivity Trial in Early Alzheimer's50%

related🔬Comprehensive analysis of immune cell subtypes in neurodegen50%

related🔬Analyze circuit-level changes in neurodegeneration using All50%

mentions🧪Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th50%

mentions🧪Lysosomal Calcium Channel Modulation Therapy50%

related🔬What cell types are most vulnerable in Alzheimer's Dise50%

related🔬What are the mechanisms underlying mitochondrial transfer be50%

mentions🧪Complement C1q Mimetic Decoy Therapy50%

related🔬What are the mechanisms underlying synaptic pruning by micro50%

related🔬The disease-associated microglia (DAM) phenotype involves TR50%

mentions🧪Purinergic P2Y12 Inverse Agonist Therapy50%

related🔬What are the mechanisms underlying mitochondrial transfer be50%

mentions🧪Gamma entrainment therapy to restore hippocampal-cortical sy50%

mentions🧪CYP46A1 Overexpression Gene Therapy50%

related🔬What are the mechanisms underlying sleep disruption as cause50%

mentions🧪Hypocretin-Neurogenesis Coupling Therapy50%

mentions🧪Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioener50%

mentions🧪PARP1 Inhibition Therapy50%

related🔬What are the mechanisms underlying tdp-43 phase separation t50%

related🔬What are the mechanisms underlying neuroinflammation resolut50%

related🔬What are the mechanisms underlying epigenetic clocks and bio50%

mentions🧪Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem50%

mentions🧪Synthetic Biology BBB Endothelial Cell Reprogramming50%

related🔬What are the mechanisms underlying sleep disruption as cause50%

mentions🧫Microbiome-Gut Barrier Signatures in ALS — Experiment Design50%

related🔬What are the mechanisms underlying tdp-43 phase separation t50%

related🔬What are the mechanisms underlying neuroinflammation resolut50%

mentions🧪Circadian Glymphatic Rescue Therapy (Melatonin-focused)50%

related🔬Can gut-brain axis modulation prevent or slow Alzheimer'50%

related🔬Investigate how lipid raft composition (cholesterol metaboli50%

related🔬What are the mechanisms underlying autophagy-lysosome pathwa50%

related🔬What are the mechanisms underlying rna binding protein dysre50%

related🔬What are the mechanisms underlying apoe4 structural biology 50%

related🔬What are the mechanisms underlying selective vulnerability o50%

mentions🧪Senescent Cell Mitochondrial DNA Release50%

mentions🧪R-Loop Resolution Enhancement Therapy50%

related🔬What are the mechanisms underlying blood-brain barrier trans50%

related🔬Investigate how lipid raft composition (cholesterol metaboli50%

related🔬What cell types are most vulnerable in Alzheimers Disease ba50%

related🔬What are the mechanisms underlying autophagy-lysosome pathwa50%

mentions🧪Selective Acid Sphingomyelinase Modulation Therapy50%

related🔬What are the mechanisms underlying blood-brain barrier trans50%

mentions🧪SIRT6-NAD+ Axis Enhancement Therapy50%

related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%

mentions🧪Arginine Methylation Enhancement Therapy50%

mentions🧪TET2-Mediated Demethylation Rejuvenation Therapy50%

related🔬What are the mechanisms underlying digital biomarkers and ai50%

related🔬Analyze circuit-level changes in neurodegeneration using All50%

related🔬What are the mechanisms underlying apoe4 structural biology 50%

mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy50%

mentions🧫Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio50%

related🧪Gamma entrainment therapy to restore hippocampal-cortical sy40%

mentions🔬Can gut-brain axis modulation prevent or slow Alzheimer'40%

mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%

related🧪Purinergic P2Y12 Inverse Agonist Therapy40%

mentions🔬What are the mechanisms underlying tdp-43 phase separation t40%

mentions🔬Senescent cell clearance as neurodegeneration therapy40%

related🧪Arginine Methylation Enhancement Therapy40%

mentions🔬What cell types are most vulnerable in Alzheimers Disease ba40%

related🧪Near-infrared light therapy stimulates COX4-dependent mitoch40%

related🧪Selective Acid Sphingomyelinase Modulation Therapy40%

mentions🔬The disease-associated microglia (DAM) phenotype involves TR40%

mentions🔬How to break the GBA-alpha-synuclein bidirectional loop for 40%

related🧪TET2-Mediated Demethylation Rejuvenation Therapy40%

mentions🔬Comprehensive analysis of immune cell subtypes in neurodegen40%

related🧪Senescent Cell Mitochondrial DNA Release40%

mentions🔬What are the mechanisms underlying senolytic therapy for age40%

related🧪Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem40%

related🧪Glial Glycocalyx Remodeling Therapy40%

related🧪Targeted APOE4-to-APOE3 Base Editing Therapy40%

related🧪Orexin-Microglia Modulation Therapy40%

related🧪HCN1-Mediated Resonance Frequency Stabilization Therapy40%

related🧪Circadian Glymphatic Rescue Therapy (Melatonin-focused)40%

related🧪Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioener40%

mentions🔬What are the most promising therapeutic strategies for targe40%

related🧪PARP1 Inhibition Therapy40%

related🧪Synthetic Biology BBB Endothelial Cell Reprogramming40%

mentions🔬What are the mechanisms underlying what are the mechanisms b40%

related🧪Ganglioside Rebalancing Therapy40%

related🧪R-Loop Resolution Enhancement Therapy40%

related🧪CYP46A1 Overexpression Gene Therapy40%

related🧪SIRT6-NAD+ Axis Enhancement Therapy40%

mentions🔬What are the mechanisms underlying blood-brain barrier trans40%

related🧪Hypocretin-Neurogenesis Coupling Therapy40%

mentions🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph40%

mentions🔬What cell types are most vulnerable in Alzheimer's Dise40%

related🧪Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th40%

related🧪Complement C1q Mimetic Decoy Therapy40%

related🧪Lysosomal Calcium Channel Modulation Therapy40%

related🧪Targeted APOE4-to-APOE3 Base Editing Therapy35%

related🧪Complement C1q Mimetic Decoy Therapy35%

related🧪Arginine Methylation Enhancement Therapy35%

related🧪Circadian Glymphatic Rescue Therapy (Melatonin-focused)35%

related🧪HCN1-Mediated Resonance Frequency Stabilization Therapy35%

related🧪Liquid-Liquid Phase Separation Modifier Therapy35%

related🧪CYP46A1 Overexpression Gene Therapy35%

related🧪PARP1 Inhibition Therapy35%

related🧪SIRT6-NAD+ Axis Enhancement Therapy35%

related🧪Ganglioside Rebalancing Therapy35%

related🧪Near-infrared light therapy stimulates COX4-dependent mitoch35%

related🧪RNA-Binding Competition Therapy for TDP-43 Cross-Seeding35%

related🧪Cholesterol-CRISPR Convergence Therapy for Neurodegeneration35%

related🧪Selective Acid Sphingomyelinase Modulation Therapy35%

related🧪Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy35%

related🧪APOE4-Selective Lipid Nanoemulsion Therapy35%

related🧪TET2-Mediated Demethylation Rejuvenation Therapy35%

related🧪Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th35%

related🧪Glial Glycocalyx Remodeling Therapy35%

related🧪Hypocretin-Neurogenesis Coupling Therapy35%

related🧪R-Loop Resolution Enhancement Therapy35%

related🧪APOE Isoform Conversion Therapy35%

related🧪Lysosomal Calcium Channel Modulation Therapy35%

related🧪Gamma entrainment therapy to restore hippocampal-cortical sy35%

related🧪Purinergic P2Y12 Inverse Agonist Therapy35%

related🧪Orexin-Microglia Modulation Therapy35%

related🔬What are the mechanisms underlying selective vulnerability o30%

related🔬What are the mechanisms underlying 4r-tau strain-specific sp30%

Reference URLs

Canonical (singular)/artifact/wiki-therapeutics-mesenchymal-stem-cell-therapy-parkinsonscanonical

Canonical (plural, REST)/artifacts/wiki-therapeutics-mesenchymal-stem-cell-therapy-parkinsonsalias

API (JSON)/api/artifacts/wiki-therapeutics-mesenchymal-stem-cell-therapy-parkinsonsapi

Citation — BibTeX/artifacts/wiki-therapeutics-mesenchymal-stem-cell-therapy-parkinsons/cite?fmt=bibtexexport

Citation — RIS/artifacts/wiki-therapeutics-mesenchymal-stem-cell-therapy-parkinsons/cite?fmt=risexport

Citation — CSL-JSON/artifacts/wiki-therapeutics-mesenchymal-stem-cell-therapy-parkinsons/cite?fmt=cslexport

Embed this artifact

Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.

HTML iframe

<iframe src="http://scidex.ai/artifact/wiki-therapeutics-mesenchymal-stem-cell-therapy-parkinsons?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[Mesenchymal Stem Cell Therapy for Parkinson&#x27;s Disease](http://scidex.ai/artifact/wiki-therapeutics-mesenchymal-stem-cell-therapy-parkinsons)

Direct URL

http://scidex.ai/artifact/wiki-therapeutics-mesenchymal-stem-cell-therapy-parkinsons

Preview

🔄 Adjacent Artifacts Recommended based on your interests

💬 Discussion

Loading comments...

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Mesenchymal Stem Cell Therapy for Parkinson's Disease

Mesenchymal Stem Cell Therapy for Parkinson's Disease

Overview

Mesenchymal Stem Cell Therapy for Parkinson's Disease

Overview

Rationale for MSC Therapy in PD

Why Neuroprotection Over Replacement?

Disease Context

Mechanism of Action

Immunomodulation

Neurotrophic Factor Secretion

Mitochondrial Transfer

Anti-Apoptotic Effects

Alpha-Synuclein Modulation

MSC Sources for PD Therapy

Clinical Trials in Parkinson's Disease

Completed and Active Trials

Key Clinical Findings

Ongoing Programs

Delivery Routes Comparison

Optimal Route Selection

Comparison: MSC vs. Dopaminergic Neuron Replacement

Complementary Approaches

Companies and Programs

Clinical-Stage Programs

Research Programs

Therapeutic Potential and Challenges

Potential Benefits

Challenges

Patient Selection Considerations

Combination Therapies

Synergistic Approaches

Research Pipeline

Safety Profile

Observed Safety in PD Trials

Long-Term Monitoring

Future Directions

Next-Generation Approaches

Clinical Development Needs

See Also

References

💬 Discussion